NCT Number: NCT07103304
Cerebral arteriovenous malformations (CAVMs) are abnormal vessels located on the surface of the brain or within the cerebral parenchyma, causing abnormal communication between the arterial and venous networks, without the interposition of the capillary bed. The main risk associated with these malformations is rupture, which causes intracranial bleeding and can lead to serious sequelae or even death. CAVMs (except those of clearly identified genetic origin [< 5%], such as mutations associated with Rendu-Osler disease) have long been considered to be of non-genetic origin.
However, somatic genetic mutations that activate the RAS/RAF/MEK/ERK (MAPK) signalling pathway have recently been identified in surgical specimens of cAVMs. Furthermore, targeted inhibition of this pathway is effective in treating these malformations in animals and appears to be effective in extracranial arteriovenous malformations, particularly superficial ones.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
University Hospital of Caen, Caen, France
Next-generation sequencing of circulating DNA in liquid biopsies is a promising new and minimally invasive approach for studying the presence of mutations in arteriovenous malformations.
The goal of treating a cAVM is to obliterate the malformation in order to prevent or avoid the risk of haemorrhage. Several therapeutic modalities may be used, which can be combined: microsurgery, endovascular embolisation, and/or radiosurgery. However, these are invasive treatments that are not without risk.
The detection of mutations by liquid biopsies would enable the development of targeted, non-invasive drug therapies against these cAVMs.
The population consists of patients aged 18 years or older with cAVMs, for whom treatment by venous embolisation was recommended during a multidisciplinary consultation meeting.
This research focuses on identifying somatic genetic mutations that activate the RAS/RAF/MEK/ERK (MAPK) signalling pathway in cAVMs. These mutations have already been identified in surgical specimens. This research aims to evaluate the genetic mutations identified by liquid biopsies on the drainage vein of cAVMs and the prevalence of each mutation.
These liquid biopsies will be performed during embolisation surgery by sampling the drainage vein of the malformation and peripheral venous blood (no additional procedures compared to usual care).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This research aims to evaluate the genetic mutations identified by liquid biopsies on the drainage vein of AVMs, and the prevalence of each mutation.
These liquid biopsies will be performed during the embolisation procedure by sampling the drainage vein of the malformation and peripheral venous blood (no additional procedures compared to standard care).
Time frame: Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate
determination of each mutation identified in the drainage vein of AVMs,
Time frame: Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate
Evaluation of the prevalence of each mutation identified in the drainage vein of AVMs, with calculation of the exact 95% confidence interval.
Time frame: Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate
Imaging characterisation of cAVMs for each of the mutations identified
Time frame: Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate
determination of each mutation identified in the peripheral vein of AVMs
Time frame: Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate
Evaluation of the prevalence of each mutation identified in the peripheral vein of AVMs, with calculation of the exact 95% confidence interval.
Contact information is provided by the study sponsor or research team.
Julien JB BUREL, Doctor
CONTACT
02 32 88 88 50 ext. +33
Vincent VF FERRANTI, ARC
CONTACT
02 32 88 82 65 ext. +33
University Hospital, Rouen
Other
Liquid Biopsies for Detecting Somatic Mutations in Sporadic Cerebral Arteriovenous Malformations. Contribution of Sampling From the Drainage Vein of the Malformation.
Acronym: BioMAV2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06259292
Arteriovenous Malformations, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT03676868
Arteriovenous Malformations, Brain Diseases
Paris, France
View Trial DetailsNCT02180958
Arteriovenous Malformations, Brain Diseases
Besançon, France
View Trial DetailsNCT02602990
Arteriovenous Malformations, Brain Diseases
Edegem, Belgium
View Trial Details